Camargo Pharmaceutical Services‘ chief executive officer, Ken Phelps, will be traveling to Tokyo, Seoul, Taipei, and Mumbai throughout this month. 

Phelps plans to hold seminars in each city on 505(b)(2) drug development, as well as meet with leading companies. This trip follows a prior trip to China, during which Camargo held a seminar with the U.S. Food and Drug Administration (FDA) on American regulatory issues, and builds on the global nature of Camargo’s clients.

“I am honored to be visiting Japan, South Korea, Taiwan, and India on this trip,” said Phelps. “I look forward to sharing the benefits and impact of the 505(b)(2) pathway and meeting with forward-thinking companies.”

Camargo is a strategic consultancy specializing in helping clients navigate the 505(b)(2) FDA approval pathway and global equivalents, from concept to approval. The approval pathway allows sponsors to leverage scientific data from existing studies and publications not conducted by or for the sponsor. By utilizing and bridging to existing data, a 505(b)(2) drug development program can result in a much less expensive and faster route to approval and market.